ARMC
BBC icon

American Research & Management Company’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

American Research & Management Company’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2K Hold
100
– – ﹤0.01% 375
2022
Q2 		$2K Hold
100
– – ﹤0.01% 363
2022
Q1 		$3K Buy
+100
New +$2.96K ﹤0.01% 361

Other funds holding BBC

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

American Research & Management Company's BBC Position: Q3 2022 in Review

American Research & Management Company held its Virtus Biotech Clinical Trials ETF (BBC) position steady in Q3 2022 at 100 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #375.

American Research & Management Company first reported a position in BBC in Q1 2022 and has held it in 3 quarters since. The position peaked at $3K in Q1 2022. 16 funds tracked by Wall St. Rank hold BBC as of Q3 2022.

  • American Research & Management Company held 100 shares of Virtus Biotech Clinical Trials ETF worth $2K as of Q3 2022.
  • American Research & Management Company left its Virtus Biotech Clinical Trials ETF share count unchanged in Q3 2022.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of American Research & Management Company's portfolio in Q3 2022, its #375 holding.
  • American Research & Management Company first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2022 and has held it in 3 quarters since.
  • American Research & Management Company's Virtus Biotech Clinical Trials ETF position peaked at $3K in Q1 2022.
  • 16 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2022.

Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.